Skin Cancer clinical trials

Explore recruiting skin cancer clinical trials.

Recruiting skin cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Skin Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

NeoMatryx - Neoadjuvant Merkel cell carcinoma therapy (Tx) with the PD-1 inhibitor Cemiplimab – A randomized, double-blind, placebo-controlled, non-comparative Phase II study

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Evaluation of efficacy and safety of Cemiplimab as first line treatment for advanced basal cell carcinoma (CEMI-first) - An open label, single arm, prospective phase II trial of the DeCOG network

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II study of L19IL2/L19TNF in patients with skin cancers amenable to intralesional treatment.

Spain, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors

Spain, Italy, France, Belgium, Czechia, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma

Czechia, Germany, Belgium, Spain, Austria, Italy +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II study of intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients with presence of injectable lesions.

Poland, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Skin Cancer trials by city

Skin Cancer in Toronto Skin Cancer in Vancouver Skin Cancer in Montreal Skin Cancer in Calgary Skin Cancer in Edmonton Skin Cancer in Ottawa Skin Cancer in Winnipeg Skin Cancer in Quebec City Skin Cancer in Hamilton Skin Cancer in Kitchener Skin Cancer in London Skin Cancer in Halifax Skin Cancer in New York Skin Cancer in Los Angeles Skin Cancer in Chicago Skin Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease